Key result
TricValve caval valve implantation linked to functional class improvement in ~89% of patients.
Why the study?
Does heterotopic transcatheter caval valve implantation with the TricValve system improve clinical and echocardiographic outcomes and reduce heart failure hospitalizations in elderly, high-risk patients with severe symptomatic tricuspid regurgitation?
Observational (n=13)
No
Does heterotopic transcatheter caval valve implantation with the TricValve system improve clinical and echocardiographic outcomes and reduce heart failure hospitalizations in elderly, high-risk patients with severe symptomatic tricuspid regurgitation?
In high-risk elderly patients with severe symptomatic tricuspid regurgitation, heterotopic caval valve implantation with TricValve was safe, abolished caval backflow, improved NYHA functional class, and reduced heart failure hospitalizations over a median 13-month follow-up.
Answers are grounded in this paper and cite their sources.
May benefit patients with severe tricuspid regurgitation; hypothesis-generating and requires randomized trials before adoption.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tomić et al. (2026) conducted an observational in Severe or torrential symptomatic tricuspid regurgitation (n=13). Transcatheter heterotopic caval valve implantation (TricValve) vs. Baseline (pre-implantation) was evaluated on NYHA functional class improvement (p=0.02). Transcatheter caval valve implantation with TricValve achieved 100% procedural success, improved functional class in 8/9 patients, and reduced heart failure hospitalizations from 1.08 to 0.28/patient-year.
Synapse has enriched 10 related papers. Consider them for comparative context: